A New Alzheimer’s Drug Is One Step Closer to Full Approval. But Access Remains a Problem
A panel of experts who advise the U.S. Food and Drug Administration (FDA) agreed on June 9 that a late-stage study of a drug for Alzheimer’s disease showed that it...
Read more













